Boehringer Ingelheim biosimilar candidate to Humira < sup > ® < /sup > accepted for EMA and FDA regulatory review

Boehringer Ingelheim biosimilar candidate to Humira® accepted for EMA and FDA regulatory review

Source: Boehringer Ingelheim Corporate News - January 17, 2017 Category: Research Source Type: news